Demand for urologists, incentives to relocate soaring

Urologists remain high on the list of in-demand medical specialists in the United States, and their services are even more sought-after than in previous years, according to recently released research. To attract them, hospitals and practices are offering more enticing salaries and other incentives.

Related Videos

Study tracks shifts in bladder management for female SCI patients

Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera’s SNM device

Ashley Winter, MD, calls for label update on low-dose vaginal estrogen

The ADVANCED-2 trial, TARA-002

Unmet needs in high risk NMIBC

Joseph Song, MD, on the emergence of new suction-based devices for stone disease

How eating disorders affect bladder and pelvic floor health

Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans

The Current Landscape of ADT in Prostate Cancer

Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC

Related Content

Advertisement

July 28th 2025

ThuFLEP and M-HoLEP achieve comparable functional outcomes in BPH

Hannah Clarke

However, M-HoLEP was superior in terms of enucleation time and efficiency, catheterization time, and hospital stay.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 25th 2025

Study shows persistent bone protective effect of menopausal hormone therapy

Hannah Clarke

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 24th 2025

FDA grants priority review to expanded indication of flibanserin in HSDD

Hannah Clarke

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.

Related Content

Advertisement

July 28th 2025

ThuFLEP and M-HoLEP achieve comparable functional outcomes in BPH

Hannah Clarke

However, M-HoLEP was superior in terms of enucleation time and efficiency, catheterization time, and hospital stay.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 25th 2025

Study shows persistent bone protective effect of menopausal hormone therapy

Hannah Clarke

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 24th 2025

FDA grants priority review to expanded indication of flibanserin in HSDD

Hannah Clarke

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.